THRX Stock Overview
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Theseus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.06 |
| 52 Week High | US$12.37 |
| 52 Week Low | US$2.05 |
| Beta | 3.98 |
| 11 Month Change | 0.74% |
| 3 Month Change | 18.37% |
| 1 Year Change | -63.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.15% |
Recent News & Updates
Recent updates
Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR
Feb 01Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans
Aug 18
Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
May 05Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
Dec 07Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Aug 11Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation
Apr 22Shareholder Returns
| THRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.5% | 1.6% | 2.2% |
| 1Y | -63.4% | 9.9% | 31.6% |
Return vs Industry: THRX underperformed the US Pharmaceuticals industry which returned 16.8% over the past year.
Return vs Market: THRX underperformed the US Market which returned 16.6% over the past year.
Price Volatility
| THRX volatility | |
|---|---|
| THRX Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THRX's share price has been volatile over the past 3 months.
Volatility Over Time: THRX's weekly volatility has decreased from 16% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 38 | n/a | theseusrx.com |
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
Theseus Pharmaceuticals, Inc. Fundamentals Summary
| THRX fundamental statistics | |
|---|---|
| Market cap | US$180.72m |
| Earnings (TTM) | -US$56.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs THRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.61m |
| Earnings | -US$56.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did THRX perform over the long term?
See historical performance and comparison